PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
Authors
Keywords
Natural killer/T-cell lymphoma, Latent membrane protein 1, Epstein–Barr virus, Programmed cell death receptor 1
Journal
Journal of Hematology & Oncology
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-10-13
DOI
10.1186/s13045-016-0341-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL
- (2016) S H Lim et al. BONE MARROW TRANSPLANTATION
- Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
- (2016) Eri Matsuki et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients
- (2016) C. Laurent et al. HAEMATOLOGICA
- Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma
- (2016) Man Nie et al. Scientific Reports
- PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model
- (2016) Shi-Dong Ma et al. PLoS Pathogens
- Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients
- (2016) C. Laurent et al. HAEMATOLOGICA
- Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy
- (2015) Xi-Wen Bi et al. ANNALS OF HEMATOLOGY
- Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma
- (2015) Semra Paydas et al. ANNALS OF HEMATOLOGY
- Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study
- (2015) Y. Yang et al. BLOOD
- Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
- (2015) Lu Jiang et al. NATURE GENETICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment
- (2015) A. A. Gru et al. Current Hematologic Malignancy Reports
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Combination of gemcitabine, l-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up
- (2014) Wang Liang et al. MEDICAL ONCOLOGY
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- High-Dose and Extended-Field Intensity Modulated Radiation Therapy for Early-Stage NK/T-Cell Lymphoma of Waldeyer's Ring: Dosimetric Analysis and Clinical Outcome
- (2013) Xi-Wen Bi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Quantification of circulating Epstein–Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance
- (2013) Y-L Kwong et al. LEUKEMIA
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
- (2012) Y.-L. Kwong et al. BLOOD
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients
- (2012) Liang Wang et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma
- (2011) S.-B. Ng et al. BLOOD
- Radiotherapy Alone With Curative Intent in Patients With Stage I Extranodal Nasal-Type NK/T-Cell Lymphoma
- (2011) Ye-Xiong Li et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
- (2011) Motoko Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
- (2010) A. Jaccard et al. BLOOD
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling
- (2010) Siok-Bian Ng et al. JOURNAL OF PATHOLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- NF- B Activation Through the Alternative Pathway Correlates with Chemoresistance and Poor Survival in Extranodal NK/T-cell Lymphoma, Nasal Type
- (2009) X. Liu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma
- (2009) Hyo Song Kim et al. LEUKEMIA & LYMPHOMA
- Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type
- (2008) Biyun Wang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
- (2008) B.-S. Kim et al. ANNALS OF ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started